Get the Stockscreener App
64.40
1.23%
-0.80
Belite Bio Inc Adr stock is traded at $64.40, with a volume of 24,096.
It is down -1.23% in the last 24 hours and up +7.92% over the past month.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
See More
Previous Close:
$65.20
Open:
$65.2
24h Volume:
24,096
Relative Volume:
0.47
Market Cap:
$2.05B
Revenue:
-
Net Income/Loss:
$-32.61M
P/E Ratio:
-54.85
EPS:
-1.1742
Net Cash Flow:
-
1W Performance:
-3.35%
1M Performance:
+7.92%
6M Performance:
+12.98%
1Y Performance:
+31.70%
1-Day Range:
$64.40
$66.89
1-Week Range:
$60.00
$67.89
52-Week Range:
$43.70
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
64.40 | 2.13B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
Belite Bio Inc Adr Stock (BLTE) Latest News
Belite Bio’s Earnings Call: Progress Amid Challenges - MSN
Promising Clinical Trials and Strong Financial Position Reinforce Buy Rating for Belite Bio - TipRanks
Q3 EPS Estimates for Belite Bio Lowered by Leerink Partnrs - Defense World
Multi factor analysis applied to Belite Bio Inc Depositary ReceiptMarket Growth Review & Fast Exit and Entry Trade Guides - Newser
Belite Bio FY2029 EPS Forecast Reduced by Leerink Partnrs - Defense World
Belite Bio’s Tinlarebant: A Promising Investment with Breakthrough Potential for Stargardt Disease - TipRanks
Benchmark Co. Reiterates Buy Rating on Belite Bio, Sets $80 Price Target - AInvest
Benchmark reiterates Buy rating on Belite Bio stock, maintains $80 price target - Investing.com Nigeria
Promising Clinical Trials and Regulatory Advancements Support Buy Rating for Belite Bio, Inc. - TipRanks
Belite Bio targets NDA submission for Tinlarebant in first half of 2026 amid strong cash runway and Phase III progress - MSN
Belite Bio Advances Retinal Disease Treatments Amid Financial Growth - TipRanks
Belite Bio's Tinlarebant: A Groundbreaking Therapy on the Cusp of Approval in Stargardt Disease and Geographic Atrophy - AInvest
Belite Bio Aims for NDA Submission by H1 2026 with Robust Cash Runway and Advancing Phase III Trials - AInvest
Belite Bio Q2 2025 presentation: expenses rise as clinical trials advance - Investing.com Canada
Earnings call transcript: Belite Bio Q2 2025 beats EPS expectations despite losses - Investing.com Nigeria
Belite Bio Q2 2025 Earnings Call Transcript - MarketBeat
Belite Bio Shares Drop Despite Clinical Milestones - TipRanks
Belite Bio reports Q2 EPS (50c), consensus (42c) - TipRanks
Belite Bio Announces Q2 2025 Financial Results and Key Clinical Milestones - TipRanks
Why Belite Bio's Widening Losses Signal a High-Probability Path to Market Leadership in Retinal Therapies - AInvest
Belite Bio's Tinlarebant: A First-in-Class Therapeutic Candidate with Dual-Indication Potential in High-Value Retinal Diseases - AInvest
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - The Globe and Mail
Belite Bio, Inc. ADR: Stock Movement Explained - TipRanks
Belite Bio Announces $15 Million Direct Offering - TipRanks
Belite Bio raises $15 million in registered direct offering - Investing.com
Belite Bio Raises $15M in Strategic Financing with Potential for Additional $15M from Warrants - Stock Titan
Belite Bio Experts Join Pivotal Retinal Disease Panel at Major Ophthalmology Conference - Stock Titan
New Strong Sell Stocks for August 4th - sharewise.com
Belite Bio Announces Q2 Earnings Call: Latest Updates on Novel Retinal Disease Therapeutics Pipeline - Stock Titan
New Strong Sell Stocks for July 22nd - The Globe and Mail
Belite Bio (BLTE) Expected to Announce Earnings on Friday - Defense World
Leading vs lagging indicators on Belite Bio Inc Depositary Receipt performanceDay Trading Plan with Entry Risk Management - Newser
A Look At The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE) - uk.finance.yahoo.com
Belite Bio Executives Share Latest Retinal Disease Breakthroughs at BTIG Biotech Conference - Stock Titan
New Strong Sell Stocks For July 22nd - Barchart.com
What analysts say about Belite Bio Inc Depositary Receipt stockConsistent wealth multiplication - jammulinksnews.com
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant - Eyes On Eyecare
Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Q2 EPS Estimates for Belite Bio Decreased by Leerink Partnrs - Defense World
Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail
Belite Bio completes enrollment in global phase 3 PHOENIX trial for geographic atrophy - Ophthalmology Times
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential - TipRanks
Phase 3 PHOENIX trial for oral GA treatment completes enrollment - Modern Retina
Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress - Investing.com India
Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations - TipRanks
Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant - TipRanks
Major Breakthrough: First-Ever Oral Treatment for Geographic Atrophy Reaches Full Phase 3 Enrollment - Stock Titan
Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):